CXCL16-positive dendritic cells enhance invariant natural killer T cell-dependent IFNγ production and tumor control

OncoImmunology

Volumn 5, Issue 6, 2016, Pages

  Veinotte, Linnea ^a,b   Gebremeskel, Simon ^a,b   Johnston, Brent ^a,b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b Beatrice Hunter Cancer Research Institute   (Canada)

Author keywords

Cell activation; chemokines; cytokines; dendritic cells; natural killer T cells

Indexed keywords

ALANINE AMINOTRANSFERASE; B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CXCR6; CXCL16 CHEMOKINE; GAMMA INTERFERON; GLYCOLIPID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12P70; INTERLEUKIN 4;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; CANCER CONTROL; CELL EXPANSION; CELL ISOLATION; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LIVER METASTASIS; LIVER TOXICITY; LUNG METASTASIS; MACROPHAGE; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; UPREGULATION;

EID: 84976299558     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1160979     Document Type: Article

References (76)

1. L.Van Kaer, V.V.Parekh, L.Wu. Invariant natural killer T cells as sensors and managers of inflammation. Trends Immunol 2013; 34:50-8; PMID:23017731; 10.1016/j.it.2012.08.009
2. J.Mattner, K.L.Debord, N.Ismail, R.D.Goff, C.Cantu3rd, D.Zhou, P.Saint-Mezard, V.Wang, Y.Gao, N.Yin et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 2005; 434:525-9; PMID:15791258; 10.1038/nature03408
3. D.Y.Wu, N.H.Segal, S.Sidobre, M.Kronenberg, P.B.Chapman. Cross-presentation of disialoganglioside GD3 to natural killer T cells. J Exp Med 2003; 198:173-81; PMID:12847141; 10.1084/jem.20030446
4. R.Cullen, E.Germanov, T.Shimaoka, B.Johnston. Enhanced tumor metastasis in response to blockade of the chemokine receptor CXCR6 is overcome by NKT cell activation. J Immunol 2009; 183:5807-15; PMID:19812206; 10.4049/jimmunol.0803520
5. S.Gebremeskel, D.R.Clattenburg, D.Slauenwhite, L.Lobert, B.Johnston. Natural killer T cell activation overcomes immunosuppression to enhance clearance of post-surgical breast cancer metastasis in mice. Oncoimmunology 2015; 4:e995562; PMID:25949924; 10.1080/2162402X.2014.995562
6. T.Kawano, J.Cui, Y.Koezuka, I.Toura, Y.Kaneko, H.Sato, E.Kondo, M.Harada, H.Koseki, T.Nakayama et al. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Vα14 NKT cells. Proc Natl Acad Sci U S A 1998; 95:5690-3; PMID:9576945; 10.1073/pnas.95.10.5690
7. Y.Hayakawa, S.Rovero, G.Forni, M.J.Smyth. α-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis. Proc Natl Acad Sci U S A 2003; 100:9464-9; PMID:12867593; 10.1073/pnas.1630663100
8. S.Gebremeskel, D.Slauenwhite, B.Johnston. Reconstitution models to evaluate natural killer T cell function in tumor control. Immunol Cell Biol 2016; 94:90-100; PMID:26095148; 10.1038/icb.2015.67
9. M.J.Smyth, K.Y.Thia, S.E.Street, E.Cretney, J.A.Trapani, M.Taniguchi, T.Kawano, S.B.Pelikan, N.Y.Crowe, D.I.Godfrey. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 2000; 191:661-8; PMID:10684858; 10.1084/jem.191.4.661
10. Y.Hayakawa, K.Takeda, H.Yagita, L.Van Kaer, I.Saiki, K.Okumura. Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways. J Immunol 2001; 166:6012-8; PMID:11342617; 10.4049/jimmunol.166.10.6012
11. + T cells and natural killer cells is essential for the antimetastatic effect of α-galactosylceramide. Blood 2002; 99:1259-66; PMID:11830474; 10.1182/blood.V99.4.1259
12. S.Motohashi, K.Nagato, N.Kunii, H.Yamamoto, K.Yamasaki, K.Okita, H.Hanaoka, N.Shimizu, M.Suzuki, I.Yoshino et al. A phase I-II study of α-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol 2009; 182:2492-501; PMID:19201905; 10.4049/jimmunol.0800126
13. T.Kawano, J.Cui, Y.Koezuka, I.Toura, Y.Kaneko, K.Motoki, H.Ueno, R.Nakagawa, H.Sato, E.Kondo et al. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science 1997; 278:1626-9; PMID:9374463; 10.1126/science.278.5343.1626
14. J.L.Matsuda, O.V.Naidenko, L.Gapin, T.Nakayama, M.Taniguchi, C.R.Wang, Y.Koezuka, M.Kronenberg. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J Exp Med 2000; 192:741-54; PMID:10974039; 10.1084/jem.192.5.741
15. +NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system. J Immunol 1999; 163:93-101; PMID:10384104
16. S.Fujii, K.Shimizu, C.Smith, L.Bonifaz, R.M.Steinman. Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 2003; 198:267-79; PMID:12874260; 10.1084/jem.20030324
17. H.Kitamura, K.Iwakabe, T.Yahata, S.Nishimura, A.Ohta, Y.Ohmi, M.Sato, K.Takeda, K.Okumura, L.Van Kaer et al. The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med 1999; 189:1121-8; PMID:10190903; 10.1084/jem.189.7.1121
18. A.C.Jaime-Ramirez, B.L.Mundy-Bosse, S.Kondadasula, N.B.Jones, J.M.Roda, A.Mani, R.Parihar, V.Karpa, T.L.Papenfuss, K.M.LaPerle et al. IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production. J Immunol 2011; 186:3401-9; PMID:21321106; 10.4049/jimmunol.1000328
19. Y.Hayakawa, K.Takeda, H.Yagita, S.Kakuta, Y.Iwakura, L.Van Kaer, I.Saiki, K.Okumura. Critical contribution of IFN-γ and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of α-galactosylceramide. Eur J Immunol 2001; 31:1720-7; PMID:11385616; 10.1002/1521-4141(200106)31:6%3c1720::AID-IMMU1720%3e3.0.CO;2-U
20. + T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol 2003; 171:5140-7; PMID:14607913; 10.4049/jimmunol.171.10.5140
21. C.Paget, M.T.Chow, H.Duret, S.R.Mattarollo, M.J.Smyth. Role of γδ T cells in α-galactosylceramide-mediated immunity. J Immunol 2012; 188:3928-39; PMID:22412194; 10.4049/jimmunol.1103582
22. + NKT cell subsets with distinct cytokine-producing capacity. Blood 2002; 100:11-6; PMID:12070001; 10.1182/blood-2001-12-0196
23. D.Slauenwhite, B.Johnston. Regulation of NKT Cell Localization in Homeostasis and Infection. Front Immunol 2015; 6:255; PMID:26074921; 10.3389/fimmu.2015.00255
24. B.Johnston, C.H.Kim, D.Soler, M.Emoto, E.C.Butcher. Differential chemokine responses and homing patterns of murine TCR αβ NKT cell subsets. J Immunol 2003; 171:2960-9; PMID:12960320; 10.4049/jimmunol.171.6.2960
25. + NKT cells patrolling liver sinusoids. PLoS Biol 2005; 3:0650-61; PMID:15799695; 10.1371/journal.pbio.0030113
26. E.Germanov, L.Veinotte, R.Cullen, E.Chamberlain, E.C.Butcher, B.Johnston. Critical role for the chemokine receptor CXCR6 in homeostasis and activation of CD1d-restricted NKT cells. J Immunol 2008; 181:81-91; PMID:18566372; 10.4049/jimmunol.181.1.81
27. T.Shimaoka, K.Seino, N.Kume, M.Minami, C.Nishime, M.Suematsu, T.Kita, M.Taniguchi, K.Matsushima, S.Yonehara. Critical role for CXC chemokine ligand 16 (SR-PSOX) in Th1 response mediated by NKT cells. J Immunol 2007; 179:8172-9; PMID:18056360; 10.4049/jimmunol.179.12.8172
28. M.Matloubian, A.David, S.Engel, J.E.Ryan, J.G.Cyster. A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nat Immunol 2000; 1:298-304; PMID:11017100; 10.1038/79738
29. A.Wilbanks, S.C.Zondlo, K.Murphy, S.Mak, D.Soler, P.Langdon, D.P.Andrew, L.Wu, M.Briskin. Expression cloning of the STRL33/BONZO/TYMSTRligand reveals elements of CC, CXC, and CX3C chemokines. J Immunol 2001; 166:5145-54; PMID:11290797; 10.4049/jimmunol.166.8.5145
30. + cells. J Leukoc Biol 2010; 87:1029-39; PMID:20181724; 10.1189/jlb.0709482
31. S.Abel, C.Hundhausen, R.Mentlein, A.Schulte, T.A.Berkhout, N.Broadway, D.Hartmann, R.Sedlacek, S.Dietrich, B.Muetze et al. The transmembrane CXC-chemokine ligand 16 is induced by IFN-γ and TNF-α and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J Immunol 2004; 172:6362-72; PMID:15128827; 10.4049/jimmunol.172.10.6362
32. M.Tohyama, K.Sayama, H.Komatsuzawa, Y.Hanakawa, Y.Shirakata, X.Dai, L.Yang, S.Tokumaru, H.Nagai, S.Hirakawa et al. CXCL16 is a novel mediator of the innate immunity of epidermal keratinocytes. Int Immunol 2007; 19:1095-102; PMID:17855433; 10.1093/intimm/dxm083
33. A.W.T.van Lieshout, R.van der Voort, L.W.J.Toonen, S.F.G.van Helden, C.G.Figdor, P.L.C.M.van Riel, T.R.D.J.Radstake, G.J.Adema. Regulation of CXCL16 expression and secretion by myeloid cells is not altered in rheumatoid arthritis. Ann Rheum Dis 2009; 68:1036-43; PMID:18628285; 10.1136/ard.2007.086611
34. S.Paust, H.S.Gill, B.-Z.Wang, M.P.Flynn, E.A.Moseman, B.Senman, M.Szczepanik, A.Telenti, P.W.Askenase, R.W.Compans et al. Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses. Nat Immunol 2010; 11:1127-35; PMID:20972432; 10.1038/ni.1953
35. I.Toura, T.Kawano, Y.Akutsu, T.Nakayama, T.Ochiai, M.Taniguchi. Inhibition of experimental tumor metastasis by dendritic cells pulsed with α-galactosylceramide. J Immunol 1999; 163:2387-91; PMID:10452972
36. H.Wang, D.Feng, O.Park, S.Yin, B.Gao. Invariant NKT cell activation induces neutrophil accumulation and hepatitis: Opposite regulation by IL-4 and IFN-γ. Hepatology 2013; 58:1474-85; PMID:23686838; 10.1002/hep.26471
37. T.Uchida, S.Horiguchi, Y.Tanaka, H.Yamamoto, N.Kunii, S.Motohashi, M.Taniguchi, T.Nakayama, Y.Okamoto. Phase I study of α-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer. Cancer Immunol Immunother 2008; 57:337-45; PMID:17690880; 10.1007/s00262-007-0373-5
38. N.Kunii, S.Horiguchi, S.Motohashi, H.Yamamoto, N.Ueno, S.Yamamoto, D.Sakurai, M.Taniguchi, T.Nakayama, Y.Okamoto. Combination therapy of in vitro-expanded natural killer T cells and α-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma. Cancer Sci 2009; 100:1092-8; PMID:19302288; 10.1111/j.1349-7006.2009.01135.x
39. K.Yamasaki, S.Horiguchi, M.Kurosaki, N.Kunii, K.Nagato, H.Hanaoka, N.Shimizu, N.Ueno, S.Yamamoto, M.Taniguchi et al. Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy. Clin Immunol 2011; 138:255-65; PMID:21185787; 10.1016/j.clim.2010.11.014
40. P.Arora, A.Baena, K.A.Yu, N.K.Saini, S.S.Kharkwal, M.F.Goldberg, S.Kunnath-Velayudhan, L.J.Carreño, M.M.Venkataswamy, J.Kim et al. A single subset of dendritic cells controls the cytokine bias of natural killer T cell responses to diverse glycolipid antigens. Immunity 2014; 40:105-16; PMID:24412610; 10.1016/j.immuni.2013.12.004
41. D.Slauenwhite, S.Gebremeskel, C.D.Doucette, D.W.Hoskin, B.Johnston. Regulation of Cytokine Polarization and T Cell Recruitment to Inflamed Paws in Mouse Collagen-Induced Arthritis by the Chemokine Receptor CXCR6. Arthritis Rheumatol 2014; 66:3001-12; PMID:25132679; 10.1002/art.38816
42. N.Fukumoto, T.Shimaoka, H.Fujimura, S.Sakoda, M.Tanaka, T.Kita, S.Yonehara. Critical roles of CXC chemokine ligand 16/scavenger receptor that binds phosphatidylserine and oxidized lipoprotein in the pathogenesis of both acute and adoptive transfer experimental autoimmune encephalomyelitis. J Immunol 2004; 173:1620-7; PMID:15265890; 10.4049/jimmunol.173.3.1620
43. O.L.Fahy, S.L.Townley, S.R.McColl. CXCL16 regulates cell-mediated immunity to Salmonella enterica serovar enteritidis via promotion of γ interferon production. Infect Immun 2006; 74:6885-94; PMID:16982830; 10.1128/IAI.01065-06
44. M.Brigl, L.Bry, S.C.Kent, J.E.Gumperz, M.B.Brenner. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat Immunol 2003; 4:1230-7; PMID:14578883; 10.1038/ni1002
45. X.Jiang, T.Shimaoka, S.Kojo, M.Harada, H.Watarai, H.Wakao, N.Ohkohchi, S.Yonehara, M.Taniguchi, K.Seino. Cutting edge: critical role of CXCL16/CXCR6 in NKT cell trafficking in allograft tolerance. J Immunol 2005; 175:2051-5; PMID:16081769; 10.4049/jimmunol.175.4.2051
46. − NKT cell population. Proc Natl Acad Sci U S A 2008; 105:11287-92; PMID:18685112; 10.1073/pnas.0801631105
47. T.Dutta, A.Spence, L.A.Lampson. Robust ability of IFN-γ to upregulate class II MHC antigen expression in tumor bearing rat brains. J Neurooncol 2003; 64:31-44; PMID:12952284
48. I.M.Svane, A.M.Engel, M.Nielsen, O.Werdelin. Interferon-γ-induced MHC class I expression and defects in Jak/Stat signalling in methylcholanthrene-induced sarcomas. Scand J Immunol 1997; 46:379-87; PMID:9350289; 10.1046/j.1365-3083.1997.d01-141.x
49. L.M.Bradley, D.K.Dalton, M.Croft. A direct role for IFN-γ in regulation of Th1 cell development. J Immunol 1996; 157:1350-8; PMID:8759714
50. D.K.Dalton, S.Pitts-Meek, S.Keshav, I.S.Figari, A.Bradley, T.A.Stewart. Multiple defects of immune cell function in mice with disrupted interferon-γ genes. Science 1993; 259:1739-42; PMID:8456300; 10.1126/science.8456300
51. A.Martín-Fontecha, L.L.Thomsen, S.Brett, C.Gerard, M.Lipp, A.Lanzavecchia, F.Sallusto. Induced recruitment of NK cells to lymph nodes provides IFN-γ for Th1 priming. Nat Immunol 2004; 5:1260-5; PMID:15531883; 10.1038/ni1138
52. Y.E.Chin, M.Kitagawa, W.C.Su, Z.H.You, Y.Iwamoto, X.Y.Fu. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science 1996; 272:719-22; PMID:8614832; 10.1126/science.272.5262.719
53. L.C.Platanias, S.Uddin, E.Bruno, M.Korkmaz, S.Ahmad, Y.Alsayed, D.Van Den Berg, B.J.Druker, A.Wickrema, R.Hoffman. CrkL and CrkII participate in the generation of the growth inhibitory effects of interferons on primary hematopoietic progenitors. Exp Hematol 1999; 27:1315-21; PMID:10428508; 10.1016/S0301-472X(99)00060-0
54. A.C.Hobeika, W.Etienne, B.A.Torres, H.M.Johnson, P.S.Subramaniam. IFN-γ induction of p21(WAF1) is required for cell cycle inhibition and suppression of apoptosis. J Interferon Cytokine Res 1999; 19:1351-61; PMID:10638704; 10.1089/107999099312812
55. + T cells requires tumor responsiveness to IFN-γ. J Immunol 2001; 166:2276-82; PMID:11160282; 10.4049/jimmunol.166.4.2276
56. C.M.Coughlin, K.E.Salhany, M.S.Gee, D.C.LaTemple, S.Kotenko, X.Ma, G.Gri, M.Wysocka, J.E.Kim, L.Liu et al. Tumor cell responses to IFN-γ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 1998; 9:25-34; PMID:9697833; 10.1016/S1074-7613(00)80585-3
57. M.Chawla-Sarkar, D.J.Lindner, Y.-F.Liu, B.R.Williams, G.C.Sen, R.H.Silverman, E.C.Borden. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003; 8:237-49; PMID:12766484; 10.1023/A:1023668705040
58. Y.J.Lee, K.L.Holzapfel, J.Zhu, S.C.Jameson, K.A.Hogquist. Steady-state production of IL-4 modulates immunity in mouse strains and is determined by lineage diversity of iNKT cells. Nat Immunol 2013; 14:1146-54; PMID:24097110; 10.1038/ni.2731
59. S.Matsumura, B.Wang, N.Kawashima, S.Braunstein, M.Badura, T.O.Cameron, J.S.Babb, R.J.Schneider, S.C.Formenti, M.L.Dustin et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol 2008; 181:3099-107; PMID:18713980; 10.4049/jimmunol.181.5.3099
60. S.Hojo, K.Koizumi, K.Tsuneyama, Y.Arita, Z.Cui, K.Shinohara, T.Minami, I.Hashimoto, T.Nakayama, H.Sakurai et al. High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. Cancer Res 2007; 67:4725-31; PMID:17510400; 10.1158/0008-5472.CAN-06-3424
61. S.M.Hald, Y.Kiselev, S.Al-Saad, E.Richardsen, C.Johannessen, M.Eilertsen, T.K.Kilvaer, K.Al-Shibli, S.Andersen, L.-T.Busund et al. Prognostic impact of CXCL16 and CXCR6 in non-small cell lung cancer: combined high CXCL16 expression in tumor stroma and cancer cells yields improved survival. BMC Cancer 2015; 15:441; PMID:26021984; 10.1186/s12885-015-1446-z
62. J.-Y.Kee, A.Ito, S.Hojo, I.Hashimoto, Y.Igarashi, K.Tsukada, T.Irimura, N.Shibahara, T.Nakayama, O.Yoshie et al. Chemokine CXCL16 suppresses liver metastasis of colorectal cancer via augmentation of tumor-infiltrating natural killer T cells in a murine model. Oncol Rep 2013; 29:975-82; PMID:23242131; 10.3892or.2012.2185
63. P.Gutwein, A.Schramme, N.Sinke, M.S.Abdel-Bakky, B.Voss, N.Obermüller, K.Doberstein, M.Koziolek, F.Fritzsche, M.Johannsen et al. Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients. Eur J Cancer 2009; 45:478-89; PMID:19070478; 10.1016/j.ejca.2008.10.023
64. J.Wang, Y.Lu, J.Wang, A.E.Koch, J.Zhang, R.S.Taichman. CXCR6 induces prostate cancer progression by the AKT/mammalian target of rapamycin signaling pathway. Cancer Res 2008; 68:10367-76; PMID:19074906; 10.1158/0008-5472.CAN-08-2780
65. M.Darash-Yahana, J.W.Gillespie, S.M.Hewitt, Y.Y.Chen, S.Maeda, I.Stein, S.P.Singh, R.B.Bedolla, A.Peled, D.A.Troyer et al. The chemokine CXCL16 and its receptor, CXCR6, as markers and promoters of inflammation-associated cancers. PLoS One 2009; 4:e6695; PMID:19690611; 10.1371/journal.pone.0006695
66. M.J.M.Gooden, V.R.Wiersma, A.Boerma, N.Leffers, H.M.Boezen, K.A.ten Hoor, H.Hollema, A.M.E.Walenkamp, T.Daemen, H.W.Nijman et al. Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity. Br J Cancer 2014; 110:1535-44; PMID:24518602; 10.1038/bjc.2014.55
67. K.Matsushita, Y.Toiyama, K.Tanaka, S.Saigusa, J.Hiro, K.Uchida, Y.Inoue, M.Kusunoki. Soluble CXCL16 in preoperative serum is a novel prognostic marker and predicts recurrence of liver metastases in colorectal cancer patients. Ann Surg Oncol 2012; 19:518-27; PMID:21845497; 10.1245/s10434-011-1993-8
68. F.Caiazza, P.M.McGowan, M.Mullooly, A.Murray, N.Synnott, N.O'Donovan, L.Flanagan, C.J.Tape, G.Murphy, J.Crown et al. Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells. Br J Cancer 2015; 112:1895-903; PMID:26010411; 10.1038/bjc.2015.163
69. R.Gangemi, A.Amaro, A.Gino, G.Barisione, M.Fabbi, U.Pfeffer, A.Brizzolara, P.Queirolo, S.Salvi, S.Boccardo et al. ADAM10 correlates with uveal melanoma metastasis and promotes in vitro invasion. Pigment Cell Melanoma Res 2014; 27:1138-48; PMID:25124714; 10.1111/pcmr.12306
70. + myeloid cells induce angiogenesis through the synergistic action of CCL2 and CXCL16 in vitro. Biochem Biophys Res Commun 2014; 443:1218-25; PMID:24388986; 10.1016/j.bbrc.2013.12.117
71. T.Isozaki, A.S.Arbab, C.S.Haas, M.A.Amin, M.D.Arendt, A.E.Koch, J.H.Ruth. Evidence that CXCL16 is a potent mediator of angiogenesis and is involved in endothelial progenitor cell chemotaxis: Studies in mice with K/BxN serum-induced arthritis. Arthritis Rheum 2013; 65:1736-46; PMID:23633118; 10.1002/art.37981
72. P.T.Lee, A.Putnam, K.Benlagha, L.Teyton, P.A.Gottlieb, A.Bendelac. Testing the NKT cell hypothesis of human IDDM pathogenesis. J Clin Invest 2002; 110:793-800; PMID:12235110; 10.1172/JCI0215832
73. X.Wen, P.Rao, L.J.Carreño, S.Kim, A.Lawrenczyk, S.A.Porcelli, P.Cresswell, W.Yuan. Human CD1d knock-in mouse model demonstrates potent antitumor potential of human CD1d-restricted invariant natural killer T cells. Proc Natl Acad Sci U S A 2013; 110:2963-8; PMID:23382238; 10.1073/pnas.1300200110
74. J.Cui, T.Shin, T.Kawano, H.Sato, E.Kondo, I.Toura, Y.Kaneko, H.Koseki, M.Kanno, M.Taniguchi. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science 1997; 278:1623-6; PMID:9374462; 10.1126/science.278.5343.1623
75. D.Unutmaz, W.Xiang, M.J.Sunshine, J.Campbell, E.Butcher, D.R.Littman. The primate lentiviral receptor Bonzo/STRL33 is coordinately regulated with CCR5 and its expression pattern is conserved Between Human and Mouse. J Immunol 2000; 165:3284-92; PMID:10975845; 10.4049/jimmunol.165.6.3284
76. S.Gebremeskel, T.Levatte, R.S.Liwski, B.Johnston, M.Bezuhly. The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer. Int J Cancer 2015; 136:234-40; PMID:24798403; 10.1002/ijc.28947